Moderna (MRNA.O) received European regulatory approval for its dual-purpose flu-COVID vaccine on Tuesday, establishing it as the first mRNA-based immunization to guard against both respiratory infections in adults 50 years and above.
This regulatory achievement opens a potential revenue pathway for Moderna as it works to expand beyond its COVID-19 business, which reached peak revenues of $18.4 billion in 2022 before experiencing substantial declines.
Key Takeaways
- First combined flu-COVID mRNA vaccine approved in Europe
- Targets adults 50+ with single-shot convenience
- US approval remains uncertain amid regulatory scrutiny
Market reaction & context
The European Medicines Agency’s Committee for Medicinal Products for Human Use endorsed marketing approval for mCombriax, enabling Moderna to challenge separate influenza vaccines from Sanofi and GSK 1. Trial results from 8,000 participants demonstrated that the combination vaccine generated immune responses statistically equivalent to current individual vaccines 2.
Moderna’s vaccine division has encountered challenges as COVID-19 demand stabilized, with respiratory vaccine revenues dropping 29% year-over-year in Q3 2025. The combination strategy could assist the company in recovering market position during seasonal vaccination periods.
Detailed analysis
The mCombriax formulation includes messenger RNA directives for producing proteins present on SARS-CoV-2 and three seasonal flu virus variants: H1N1, H3N2, and influenza B Victoria lineage 1. Similar to current COVID and flu immunizations, the formula will receive periodic updates to align with prevalent viral strains.
European health statistics referenced by regulators indicated over 281 million COVID-19 infections documented in the region through February 2026, while seasonal flu generates up to 50 million symptomatic cases yearly throughout the European Economic Area 1. The primary adverse effects encompass injection site discomfort, tiredness, muscle aches, and fever, with symptoms generally persisting for three days 1.
Outlook & management quote
“The CHMP’s positive opinion represents an important milestone for respiratory virus vaccination and for Moderna,” CEO Stephane Bancel said in a statement 3. “Combination vaccines have the potential to simplify vaccination and support improved health outcomes.”
The European Commission must now validate the recommendation before marketing can commence across EU nations. Individual country authorities will determine vaccine deployment decisions and formulate recommendations regarding target demographics based on their particular epidemiological circumstances 1.
US regulatory uncertainty
Moderna faces a complex route to US authorization after the FDA initially declined to evaluate the application in 2024, subsequently reversing its position following industry advocacy 4. The Trump administration’s selection of vaccine skeptics for senior health roles has introduced further regulatory ambiguity for mRNA platforms.
The company had previously retracted its US filing after the FDA demanded supplementary data, then resubmitted with an established August 2026 decision deadline 5. This regulatory split between Europe and the US illustrates different methodologies for assessing combination vaccines.
Conclusion
European authorization of mCombriax represents a notable regulatory achievement for combined respiratory immunizations, potentially streamlining seasonal vaccination programs. Nevertheless, Moderna’s commercial performance will hinge on pricing discussions with individual EU countries and ultimate US market entry.
The vaccine constitutes Moderna’s fourth commercialized product in Europe, broadening its lineup beyond COVID-19 as the organization aims to build a more comprehensive infectious disease portfolio.
Not investment advice. For informational purposes only.
References
1European Medicines Agency (February 27, 2026). “First combined COVID-19 and influenza vaccine for people 50 years and older”. European Medicines Agency. Retrieved April 21, 2026.
2Chris Dall, MA (February 27, 2026). “European regulators recommend approval of combined mRNA vaccine for flu and COVID”. CIDRAP. Retrieved April 21, 2026.
3Jennifer Boggs (February 27, 2026). “Moderna’s combo flu/COVID vaccine gets thumbs up in EU”. BioWorld. Retrieved April 21, 2026.
4Sam Becker (February 27, 2026). “Europe just approved a combined flu and COVID shot. Why hasn’t the US?”. Fast Company. Retrieved April 21, 2026.
5Kevin Dunleavy (February 27, 2026). “After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review'”. Fierce Pharma. Retrieved April 21, 2026.